FDA approves first nasal spray treatment for severe depression

The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe depression. It is now the first-ever stand-alone therapy for treatment-resistant depression.  NBC News Health

​The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe depression. It is now the first-ever stand-alone therapy for treatment-resistant depression.